Replies to post #125945 on Biotech Values

[NP1986]

Like I said, I will take my chances that all of the above simply isn't "by chance".

One of the trials is double-blinded - how would the patient know if he/she received vismodegib? And none of the trials are testing vismodegib as a single agent. Gemcitabine may not be revolutionary, but it does have established efficacy in pancreatic cancer. A complete response would not simply occur by "chance" - you'd expect to see at least one or two if the trial is enrolling several patients.

I don't know if the hedgehog inhibitors will or will not work, but I don't think making a judgement based on testimonials will necessarily give you any more clarity in this case.